home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 05/07/19

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need

VANCOUVER, Washington, May 07, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, tod...
CYDY - CytoDyn's Monotherapy Trial with Leronlimab (PRO 140) Reaches its Ultimate Goals

New data shows 525 mg dose achieves 95% response rate after the first 10 weeks of monotherapy with leronlimab Over 110 patients have reached almost one year of suppressed viral load with monotherapy on original dose of 350 mg or higher dosages Half-life of leronlimab is now con...

CYDY - CytoDyn (CYDY) Investor Presentation - Slideshow

The following slide deck was published by CytoDyn Inc. in conjunction with this Read more ...

CYDY - CytoDyn to Present at ThinkEquity Conference on May 2, 2019

VANCOUVER, Washington, April 29, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), CytoDyn, a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that management will present a compa...
CYDY - ASM Microbe 2019 Conference Grants Both Poster and Oral Presentations to CytoDyn for its Pivotal Study of Leronlimab (PRO 140) which Demonstrated Superior Efficacy and Safety in Heavily Treatment-Experienced HIV Patients

VANCOUVER, Washington, April 04, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, to...

CYDY - Venture Breakfast Bits, by 24/7 Market News

DENVER, Colo., April 2, 2019- (24/7MarketNews via COMTEX) Venture Market News for April 2, 2019. CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval VANCOUVER, Washington, April...

CYDY - CytoDyn and Samsung Biologics inks deal to manufacture leronlimab

CytoDyn ( OTCQB:CYDY ) has entered into an agreement with Samsung BioLogics for the clinical and commercial manufacturing of $1B worth of leronlimab (PRO 140). More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

CYDY - CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval

VANCOUVER, Washington, April 02, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, to...

CYDY - CytoDyn Announces Data From Two Studies at the AACR Annual Meeting

VANCOUVER, Washington, April 01, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, hi...

CYDY - NanoString Technologies Fundraising Signals Inflection Point In Strategy

Editor's note: Seeking Alpha is proud to welcome Theodore Zucconi as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » NanoStri...
Previous 10 Next 10